





ABOUT OUR PROGRAM




One of the
LARGEST

pediatric cancer centers
in the country, treating
477
new cancer patients
in 2019

Largest
pediatric sickle cell
disease program
in the nation, treating
more than
2,000
unique pediatric
sickle cell disease
patients each year



Performed **74**
BMTs in 2019,
making us one of the
largest
pediatric BMT programs
in the country



108 faculty members—**6 times** our size in 2000
50 advanced practice providers



Developed a new treatment
strategy called the
Atlanta Protocol, which
has been adopted internationally
to care for hemophilia A
patients with inhibitors



One of only **19**
¹³¹I-MIBG therapy sites for the
COG Phase III trial, and leader
of a national trial combining
MIBG with immunotherapy for
neuroblastoma patients



Pediatric component of the
Winship Cancer Institute
of Emory University,
the **first and only**
comprehensive NCI-designated
cancer institute in Georgia



Ranked **No. 1** in the country
for COG therapeutic clinical trial
enrollment, with more than
400 clinical studies
available to our patients




Treated more than
8,500 patients
in 2019 across
three campuses



One of 21 premier
pediatric oncology programs
making up the **COG Phase I**
and **Pilot Consortium**



Cared for nearly
1,000 patients
in our Cancer
Survivor Program in 2019



**Cancer Predisposition
Program** provides
comprehensive, pediatric-
focused genetic counseling
and surveillance, as well as
cutting-edge genetic tools




Treated patients from
43 states
over the last 5 years



**Immunohematology and
Immune Dysregulation
Program** provides targeted
immune modulatory and
biological therapies based on
immune profiles and genetics



Generate direct costs of
more than **\$21.3** million
per year in **extramural
research funding**, including
more than **\$12.3** million from **NIH**



Offering proton therapy to
pediatric oncology patients at the
Emory Proton Therapy Center
in collaboration with
Winship Cancer Institute
of Emory University



Member of the prestigious
**Pediatric Brain Tumor
Consortium (PBTC)**—
one of **11** centers
nationwide



**Precision Medicine
Program** allows for genomic
profiling of high-risk tumors
to tailor clinical care



More than **40** **Dev-T** trials open
for enrollment, 13 of which are
investigator-initiated by our team,
with anticipated expansion in 2020
thanks to a **\$20** million commitment
from the **Peach Bowl LegACy Fund**



Bone Marrow Failure Program
provides multidisciplinary
care to children with
inherited or acquired
bone marrow failure syndromes



Visit **choa.org/cancer** to learn more about our program.